[go: up one dir, main page]

MA50561A - Composés inhibiteurs de btk - Google Patents

Composés inhibiteurs de btk

Info

Publication number
MA50561A
MA50561A MA050561A MA50561A MA50561A MA 50561 A MA50561 A MA 50561A MA 050561 A MA050561 A MA 050561A MA 50561 A MA50561 A MA 50561A MA 50561 A MA50561 A MA 50561A
Authority
MA
Morocco
Prior art keywords
btk inhibitor
inhibitor compounds
compounds
btk
inhibitor
Prior art date
Application number
MA050561A
Other languages
English (en)
Other versions
MA50561B1 (fr
Inventor
Kenneth James Henry Jr
Albert Khilevich
Steven Lee Kuklish
Katherine Marie Partridge
Steven James Quimby
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA50561A publication Critical patent/MA50561A/fr
Publication of MA50561B1 publication Critical patent/MA50561B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA50561A 2017-11-06 2018-10-30 Composés inhibiteurs de btk MA50561B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762581967P 2017-11-06 2017-11-06
PCT/US2018/058104 WO2019089512A1 (fr) 2017-11-06 2018-10-30 Composés inhibiteurs de btk

Publications (2)

Publication Number Publication Date
MA50561A true MA50561A (fr) 2020-09-16
MA50561B1 MA50561B1 (fr) 2022-03-31

Family

ID=64277913

Family Applications (1)

Application Number Title Priority Date Filing Date
MA50561A MA50561B1 (fr) 2017-11-06 2018-10-30 Composés inhibiteurs de btk

Country Status (35)

Country Link
US (1) US11542249B2 (fr)
EP (1) EP3707133B1 (fr)
JP (1) JP6920553B2 (fr)
KR (1) KR102410202B1 (fr)
CN (1) CN111278818B (fr)
AR (1) AR113796A1 (fr)
AU (1) AU2018360478B2 (fr)
BR (1) BR112020006749A2 (fr)
CA (1) CA3080123C (fr)
CL (1) CL2020001089A1 (fr)
CR (1) CR20200183A (fr)
CY (1) CY1124994T1 (fr)
DK (1) DK3707133T3 (fr)
DO (1) DOP2020000103A (fr)
EA (1) EA039398B1 (fr)
EC (1) ECSP20024395A (fr)
ES (1) ES2904843T3 (fr)
HR (1) HRP20220178T1 (fr)
HU (1) HUE057987T2 (fr)
IL (1) IL273778B (fr)
JO (1) JOP20200104A1 (fr)
LT (1) LT3707133T (fr)
MA (1) MA50561B1 (fr)
MD (1) MD3707133T2 (fr)
MX (1) MX2020004435A (fr)
PE (1) PE20201168A1 (fr)
PH (1) PH12020550791B1 (fr)
PL (1) PL3707133T3 (fr)
PT (1) PT3707133T (fr)
RS (1) RS62805B1 (fr)
SG (1) SG11202003178PA (fr)
SI (1) SI3707133T1 (fr)
TW (1) TWI694995B (fr)
UA (1) UA126079C2 (fr)
WO (1) WO2019089512A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3972603T3 (pl) * 2019-05-23 2025-02-03 Novartis Ag Sposoby leczenia zespołu sjögrena przy użyciu inhibitora kinazy tyrozynowej brutona

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2426109B1 (fr) * 2007-10-23 2013-12-18 F. Hoffmann-La Roche AG Nouveaux inhibiteurs de kinase
AU2011249912A1 (en) * 2010-05-07 2012-11-29 Genentech, Inc. Pyridone and aza-pyridone compounds and methods of use
AR082590A1 (es) * 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
KR20150144817A (ko) 2011-06-10 2015-12-28 메르크 파텐트 게엠베하 Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법
WO2014093230A2 (fr) * 2012-12-10 2014-06-19 Merck Patent Gmbh Compositions et procédés de fabrication de composés pyrimidine et pyridine ayant une activité inhibitrice de btk
GB2516303A (en) 2013-07-18 2015-01-21 Redx Pharma Ltd Compounds
US9512084B2 (en) * 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
US10526309B2 (en) 2015-10-02 2020-01-07 The University Of North Carolina At Chapel Hill Pan-TAM inhibitors and Mer/Axl dual inhibitors

Also Published As

Publication number Publication date
IL273778B (en) 2022-06-01
EA039398B1 (ru) 2022-01-24
AU2018360478B2 (en) 2020-09-17
EP3707133B1 (fr) 2021-12-15
CA3080123C (fr) 2021-11-09
PE20201168A1 (es) 2020-10-28
ES2904843T3 (es) 2022-04-06
MD3707133T2 (ro) 2022-07-31
RS62805B1 (sr) 2022-02-28
AU2018360478A1 (en) 2020-04-23
BR112020006749A2 (pt) 2020-10-06
DK3707133T3 (da) 2022-01-03
PH12020550791A1 (en) 2021-04-12
LT3707133T (lt) 2022-01-25
CR20200183A (es) 2020-05-30
CL2020001089A1 (es) 2020-10-23
JP2021501749A (ja) 2021-01-21
JP6920553B2 (ja) 2021-08-18
ECSP20024395A (es) 2020-06-30
CN111278818A (zh) 2020-06-12
US11542249B2 (en) 2023-01-03
CA3080123A1 (fr) 2019-05-09
SI3707133T1 (sl) 2022-02-28
MX2020004435A (es) 2020-08-06
CN111278818B (zh) 2023-03-28
PL3707133T3 (pl) 2022-04-04
WO2019089512A1 (fr) 2019-05-09
MA50561B1 (fr) 2022-03-31
UA126079C2 (uk) 2022-08-10
AR113796A1 (es) 2020-06-10
PH12020550791B1 (en) 2024-04-17
HRP20220178T1 (hr) 2022-04-29
NZ764452A (en) 2023-09-29
SG11202003178PA (en) 2020-05-28
TW201930293A (zh) 2019-08-01
EP3707133A1 (fr) 2020-09-16
EA202090843A1 (ru) 2020-07-24
IL273778A (en) 2020-05-31
CY1124994T1 (el) 2023-01-05
DOP2020000103A (es) 2020-09-15
KR20200060480A (ko) 2020-05-29
US20200290997A1 (en) 2020-09-17
PT3707133T (pt) 2022-01-27
TWI694995B (zh) 2020-06-01
HUE057987T2 (hu) 2022-06-28
JOP20200104A1 (ar) 2022-10-30
KR102410202B1 (ko) 2022-06-22

Similar Documents

Publication Publication Date Title
EP3720430A4 (fr) Composés benzocarbonyle
EP3691623A4 (fr) Composés de benzosulfonyle
MA49701A (fr) Composés immunomodulateurs
MA52948A (fr) Composés
MA47131A (fr) Composés benzyl-amide phosphodiamide antiviraux
MA51669A (fr) Composés
EP3609871A4 (fr) Composés d'amide aryl cyclopropyl-amino-isoquinolinyl
MA46242A (fr) Composés inhibiteurs de bêta-lactamase
MA53003A (fr) Composés
EP3397629A4 (fr) Composés inhibiteurs de métallo-enzymes
EP3464336A4 (fr) Composés
DK4039675T3 (da) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl forbindelser
LT4101855T (lt) Priešnavikiniai junginiai
MA50504A (fr) Composés antibactériens
EP3310352A4 (fr) Composés cristallins
LT3867247T (lt) Naujieji junginiai
MA52946A (fr) Composés
MA49880A (fr) Composés anticancéreux
MA51221A (fr) Composés de pyrazolopyridinone
EP3713941A4 (fr) Composés de pyrazolopyridinone
EP3693360C0 (fr) Composés hétérocycliques
DK3672941T3 (da) Pyridylpyridonforbindelser
EP3504269A4 (fr) Composés de fluoroélastomère
MA50561A (fr) Composés inhibiteurs de btk
EP3325497A4 (fr) Composés quinstatine